Ubs Group Ag E Ffector Therapeutics, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.37 - $0.69 $289 - $539	-782 Reduced 7.92%	9,092 $4,000
Q3 2023 Nov 09, 2023	BUY	$0.49 - $0.88 $4,838 - $8,689	9,874 New	9,874 $5,000
Q1 2023 May 12, 2023	SELL	$0.35 - $0.67 $1,697 - $3,248	-4,849 Reduced 18.46%	21,414 $7,000
Q4 2022 Feb 08, 2023	BUY	$0.38 - $0.66 $3,687 - $6,405	9,705 Added 58.61%	26,263 $11,000
Q3 2022 Nov 10, 2022	BUY	$0.08 - $1.41 $1,324 - $23,346	16,558 New	16,558 $9,000
Q2 2022 Aug 10, 2022	SELL	$1.3 - $3.84 $183 - $541	-141 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.85 - $8.2 $8,701 - $18,532	-2,260 Reduced 94.13%	141 $1,000
Q4 2021 Feb 14, 2022	BUY	$5.71 - $13.15 $13,709 - $31,573	2,401 New	2,401 $20,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.